Elise Chapiro,Elodie Pramil,M'boyba Diop,Damien Roos-Weil,Clémentine Dillard,Clémentine Gabillaud,Karim Maloum,Catherine Settegrana,Lucile Baseggio,Jean-François Lesesve,Mélanie Yon,Ludovic Jondreville,Claude Lesty,Frédéric Davi,Magali Le Garff-Tavernier,Nathalie Droin,Philippe Dessen,Caroline Algrin,Véronique Leblond,Jean Gabarre,Simon Bouzy,Virginie Eclache,Baptiste Gaillard,Evelyne Callet-Bauchu,Marc Muller,Christine Lefebvre,Nathalie Nadal,Antoine Ittel,Stéphanie Struski,Marie-Agnès Collonge-Rame,Benoit Quilichini,Sandra Fert-Ferrer,Nathalie Auger,Isabelle Radford-Weiss,Lena Wagner,Sebastian Scheinost,Thorsten Zenz,Santos A Susin,Olivier A Bernard,Florence Nguyen-Khac,the Groupe Francophone de Cytogénétique Hématologique (GFCH),the French Innovative Leukemia Organization (FILO)

Abstract:B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechanisms are poorly understood. Our cytogenetic and molecular assessments of 34 patients with B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype was complex (≥3 abnormalities) in 73% of the patients and highly complex (≥5 abnormalities) in 45%. The most frequent chromosomal aberrations were translocations involving MYC [t(MYC)] (62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p (23%). Twenty-six (76%) of the 34 patients exhibited an MYC aberration, resulting from mutually exclusive translocations or gains. Whole-exome sequencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, SETD2, CHD2, CXCR4, and BCLAF1. The majority of B-PLL used the IGHV3 or IGHV4 subgroups (89%) and displayed significantly mutated IGHV genes (79%). We identified 3 distinct cytogenetic risk groups: low risk (no MYC aberration), intermediate risk (MYC aberration but no del17p), and high risk (MYC aberration and del17p) (P = .0006). In vitro drug response profiling revealed that the combination of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodomain and extra-terminal motif inhibitor targeting MYC) was associated with significantly lower viability of B-PLL cells harboring a t(MYC). We concluded that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting MYC may be a useful treatment option in this disease.

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53